Nano-engineering Nanomedicines with Customized Functions for Tumor Treatment Applications

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Aug 2

PMID 37533106

Authors

Yuxin Wang

Shimei Li

Xiangling Ren

Shiping Yu

Xianwei Meng

Affiliations

Soon will be listed here.

Abstract

Nano-engineering with unique "custom function" capability has shown great potential in solving technical difficulties of nanomaterials in tumor treatment. Through tuning the size and surface properties controllablly, nanoparticles can be endoewd with tailored structure, and then the characteristic functions to improve the therapeutic effect of nanomedicines. Based on nano-engineering, many have been carried out to advance nano-engineering nanomedicine. In this review, the main research related to cancer therapy attached to the development of nanoengineering nanomedicines has been presented as follows. Firstly, therapeutic agents that target to tumor area can exert the therapeutic effect effectively. Secondly, drug resistance of tumor cells can be overcome to enhance the efficacy. Thirdly, remodeling the immunosuppressive microenvironment makes the therapeutic agents work with the autoimmune system to eliminate the primary tumor and then prevent tumor recurrence and metastasis. Finally, the development prospects of nano-engineering nanomedicine are also outlined.

Citing Articles

ROS-Responsive Nanoprobes for Bimodal Imaging-Guided Cancer Targeted Combinatorial Therapy.

Jiang F, Liu S, Wang L, Chen H, Huang Y, Cao Y Int J Nanomedicine. 2024; 19:8071-8090.

PMID: 39130685 PMC: 11317049. DOI: 10.2147/IJN.S467512.

Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.

Chen S, He Y, Huang X, Shen Y, Zou Q, Yang G J Nanobiotechnology. 2024; 22(1):348.

PMID: 38898486 PMC: 11188166. DOI: 10.1186/s12951-024-02612-3.

Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review.

Ghosh S, Bhatti G, Sharma P, Kandimalla R, Mastana S, Bhatti J Cell Mol Neurobiol. 2023; 44(1):6.

PMID: 38104307 PMC: 11397842. DOI: 10.1007/s10571-023-01434-5.

References

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

Halder S, Basu S, Lall S, Ganti A, Batra S, Seshacharyulu P . Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?. Expert Opin Ther Targets. 2023; 27(4-5):305-324. PMC: 10330690. DOI: 10.1080/14728222.2023.2218613. View

Dai Y, Xu C, Sun X, Chen X . Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017; 46(12):3830-3852. PMC: 5521825. DOI: 10.1039/c6cs00592f. View

Han F, Vivekchand S, Soeriyadi A, Zheng Y, Gooding J . Thermoresponsive plasmonic core-satellite nanostructures with reversible, temperature sensitive optical properties. Nanoscale. 2018; 10(9):4284-4290. DOI: 10.1039/c7nr09218k. View

Wartenberg M, Ling F, Schallenberg M, Baumer A, Petrat K, Hescheler J . Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem. 2001; 276(20):17420-8. DOI: 10.1074/jbc.M100141200. View

Jhaveri A, Deshpande P, Torchilin V . Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release. 2014; 190:352-70. DOI: 10.1016/j.jconrel.2014.05.002. View

Schafer F, Buettner G . Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001; 30(11):1191-212. DOI: 10.1016/s0891-5849(01)00480-4. View

DAddio S, Prudhomme R . Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011; 63(6):417-26. DOI: 10.1016/j.addr.2011.04.005. View

Zan Y, Dai Z, Liang L, Deng Y, Dong L . Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment. Drug Deliv. 2019; 26(1):1080-1091. PMC: 6882497. DOI: 10.1080/10717544.2019.1654040. View

10.

Ou H, Cheng T, Zhang Y, Liu J, Ding Y, Zhen J . Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells. Acta Biomater. 2017; 65:339-348. DOI: 10.1016/j.actbio.2017.10.034. View

11.

Shi P, Cheng Z, Zhao K, Chen Y, Zhang A, Gan W . Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J Nanobiotechnology. 2023; 21(1):103. PMC: 10031984. DOI: 10.1186/s12951-023-01826-1. View

12.

Nikravan G, Haddadi-Asl V, Salami-Kalajahi M . Synthesis of dual temperature - and pH-responsive yolk-shell nanoparticles by conventional etching and new deswelling approaches: DOX release behavior. Colloids Surf B Biointerfaces. 2018; 165:1-8. DOI: 10.1016/j.colsurfb.2018.02.010. View

13.

Kapse-Mistry S, Govender T, Srivastava R, Yergeri M . Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014; 5:159. PMC: 4090910. DOI: 10.3389/fphar.2014.00159. View

14.

Nawaz F, Kipreos E . Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022; 33(3):159-174. PMC: 8923831. DOI: 10.1016/j.tem.2021.12.003. View

15.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

16.

Su Z, Dong S, Zhao S, Liu K, Tan Y, Jiang X . Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat. 2021; 58:100777. DOI: 10.1016/j.drup.2021.100777. View

17.

Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X . Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Lett. 2021; 21(10):4231-4240. DOI: 10.1021/acs.nanolett.1c00209. View

18.

Ma M, Yan F, Yao M, Wei Z, Zhou D, Yao H . Template-Free Synthesis of Hollow/Porous Organosilica-FeO Hybrid Nanocapsules toward Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound Therapy. ACS Appl Mater Interfaces. 2016; 8(44):29986-29996. DOI: 10.1021/acsami.6b10370. View

19.

Huang Y, Kim B, Chan C, Hahn S, Weissman I, Jiang W . Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018; 18(3):195-203. PMC: 5922422. DOI: 10.1038/nri.2017.145. View

20.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View